-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Neuroblastoma Drug Details: Tazemetostat hydrobromide (Tazverik) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLM-101 in Congenital Disorder of Glycosylation Type I A
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GLM-101 in Congenital Disorder of Glycosylation Type I A Drug Details: GLM-101 is under development...
-
Product Insights
NewThrombotic Microangiopathy – Drugs In Development, 2024
Empower your strategies with our Thrombotic Microangiopathy – Drugs In Development, 2024 report and make more profitable business decisions. Thrombotic Microangiopathy is a life-threatening group of hematological diseases characterized by hemolytic anemia (destruction of red blood cells), thrombocytopenia, and microthrombi leading to ischemic tissue injury. In severe cases, TMA leads to kidney injury. Mutations in the ADAMTS13 gene and atypical hemolytic uremic syndrome cause TMA. It can also be caused by infectious diseases, blood-borne diseases, drug-induced etc. Complete blood count to...
-
Product Insights
NewBiliary Tumor – Drugs In Development, 2024
Empower your strategies with our Biliary Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Bile duct cancer, or cholangiocarcinoma, is a rare malignancy arising from malignant cells forming in the bile ducts. It presents in two main types: intrahepatic, occurring inside the liver, and extrahepatic, forming outside the liver. Extrahepatic bile duct cancer further divides into perihilar, found where the right and left bile ducts meet, and distal, located where liver and gallbladder ducts merge. Symptoms...
-
Product Insights
NewVulvar Cancer – Drugs In Development, 2024
Empower your strategies with our Vulvar Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. The Vulvar Cancer drugs in...
-
Product Insights
NewVaginal Cancer – Drugs In Development, 2024
Empower your strategies with our Vaginal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Vaginal cancer is a rare cancer that occurs in the vagina. Symptoms includes watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, and vaginal bleeding. Risk factors include age, smoking, HIV infection, and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy, and chemotherapy. The Vaginal Cancer drugs in development market research report provide comprehensive information...
-
Product Insights
NewPenile Cancer – Drugs In Development, 2024
Empower your strategies with our Penile Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Penile cancer is a rare malignancy that develops on the skin or tissues of the penis. It occurs when normal cells in the penis undergo genetic mutations, leading to uncontrolled growth and the formation of a cancerous tumor. Early stages of penile cancer might not cause noticeable symptoms. As the disease progresses, signs and symptoms may include changes in skin color or...
-
Product Insights
NewAnal Cancer – Drugs In Development, 2024
Empower your strategies with our Anal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, and narrowing of stool. Predisposing factors include HPV infections, smoking, and lowered immunity. The Anal Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Anal...
-
Product Insights
NewRectal Cancer – Drugs In Development, 2024
Empower your strategies with our Rectal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources, and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as...